VISUAL DISTURBANCES IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH CRIZOTINIB

被引：0
|
作者：
Besse, B. [1 ]
Salgia, R. [2 ]
Solomon, B. [3 ]
Shaw, A. [4 ]
Kim, D. [5 ]
Schachar, R. [6 ]
Wilner, K. [7 ]
Reisman, A. [8 ]
Bartlett, C. H. [9 ]
Iyer, S. [10 ]
机构：
[1] Inst Cancerol Gustave Roussy, Dept Med, Villejuif, France
[2] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[6] Pfizer, Specialty Care, La Jolla, CA USA
[7] Pfizer Oncol, Res & Dev, La Jolla, CA USA
[8] Pfizer Inc, Stat, New York, NY USA
[9] Pfizer, Oncol, New York, NY USA
[10] Pfizer Oncol, Global Outcomes Res, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [1] Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
    Salgia, Ravi
    Solomon, Benjamin J.
    Shaw, Alice Tsang
    Camidge, D. Ross
    Evans, Tracey L.
    Kim, Dong-Wan
    Shi, Yuankai
    Han, Ji-Youn
    De Pas, Tommaso Martino
    Ou, Sai-Hong Ignatius
    Bartlett, Cynthia Huang
    Wilner, Keith D.
    Reisman, Arlene
    Iyer, Shrividya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] VISUAL EFFECTS IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CRIZOTINIB
    Yang, P. -C.
    Salgia, R.
    Solomon, B.
    Shaw, A. T.
    Camidge, D. R.
    Evans, T. L.
    Kim, D. -W.
    Shi, Y.
    Han, J. -Y.
    De Pas, T. M.
    Ou, S. -H. I.
    Bartlett, C. H.
    Wilner, K.
    Reisman, A.
    Iyer, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 44 - 44
  • [3] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [4] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [6] Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK1) non-small cell lung cancer (NSCLC) patients (Pts)
    Reckamp, K. L.
    Lee, J.
    Huang, J.
    Proskorovsky, I.
    Reichmann, W.
    Krotneva, M.
    Kerstein, D.
    Huang, H.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [7] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Clinical implications of cardiotoxicity and pharmacokinetics of alectinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
    Pruis, M.
    Veerman, M. G. D.
    Hassing, C.
    Lanser, D.
    Paats, M. S.
    Mathijssen, R. H.
    Manintveld, O.
    Dingemans, A-M. C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S63 - S63
  • [9] Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
    Goto, Y.
    Yamamoto, N.
    Masters, E.
    Kikkawa, H.
    Mardekian, J.
    Wiltshire, R.
    Togo, K.
    Ma, H.
    Ohe, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S878 - S879
  • [10] Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
    Leal, T.
    Wakelee, H.
    Reckamp, K.
    Waqar, S.
    Patel, S.
    Blumenschein, G.
    Neal, J.
    Harrow, K.
    Holzhausen, A.
    Liang, C.
    Dukart, G.
    Horn, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S156 - S156
12345